The Savva et al. team evaluated the impact of various polymorphisms in the TNF and TLR4 genes on the treatment response with anti-TNF drugs in 190 Caucasian patients (from Greece) diagnosed with HS, 32 of whom were treated with ADA [103]. This evidence concerns the gene TNF and histiocytic sarcoma.